Is Folate an Aetiological Factor for Colorectal Cancer Onset? A Case-Control Study

Asma Kassab¹, Awatef Msolly*, Shinji Fujimori², Ramzi Lakhdar³ and Abdelhedi Miled¹

¹Biochemistry laboratory, Farhat Hached University Hospital, Sousse, Tunisia
²Department of Gastroenterology, Nippon Medical School, Graduate school of medicine, Tokyo, Japan
³Department of Biochemistry and Molecular Biology, Pharmaceutical Faculty, Monastir, Tunisia

Abstract

The aim of this study was to investigate the correlation of serum folate concentration in newly diagnosed patients with colorectal cancer. Patient population consisted of 101 sporadic colon cases, newly diagnosed, non-alcoholic and non-multivitamins users. Control population consisted of 130 healthy subjects. Venous blood was collected prior to the first chemotherapy intervention. Folate, vitamin B12 and homocysteine were measured using an automated analyzer system. Vitamin B6 was quantified using an enzyme immunoassay. Insulin and leptin were measured using immunoradiometric assay. Folic acid and vitamin B12 were significantly increased in cases compared to controls (15 ± 7 ng/ml vs. 10 ± 4 ng/ml, P=0.01; 330 ± 200 pg/ml vs. 220 ± 100 pg/ml, P=0.02) respectively. Folic acid and BMI were inversely correlated in controls (r=-0.32; P=0.05). There was no significant difference of homocysteine and vitamin B6 between cases and controls. Leptin and insulin were significantly higher in cases with BMI ≥ 27 than in controls with BMI ≥ 27 (16 ± 7 ng/ml vs. 14 ± 7 ng/ml; 32 ± 18 µU/ml vs. 29 ± 11 µU/ml). However, stratifying leptin and insulin by cancer stages yielded to no clear pattern. Folate may be implicated as a potential aetiological factor for colorectal cancer.

Keywords: Colorectal cancer; Folate; Leptin; Insulin; Vitamin-B12

Introduction

Colorectal cancer (CRC) is the second most common malignant disease in developed countries, with 1 million new cases and 500 000 deaths worldwide every year [1], and it is the third cancer type leading to death in both men and woman in industrialized countries [2]. In Tunisia CRC is the first cause of death in the digestive cancer which is drawing the public health researchers’ attention. The absolute rate of colon cancer is being amplified by 5.3% (95% CI: +2.7%, +7.9%) in males and by 2.6% (95% CI: +0.1%, +5.1%) in females [3]. Therefore, major concerns must be provided in order to find out promoter factors and reduce the intensity of this disease on both the individual and the wider society.

Folate, as 5,10-methylene tetrahydrofolate, is an essential 1-C donor in DNA synthesis and, as 5-methyl tetrahydrofolate, in DNA methylation. The excess of 5,10-methylene tetrahydrofolate, promotes the methylation of deoxuridine-5'-monophosphate (dUMP) to deoxythymidine-5'-monophosphate (dTMP). 5-methyltetrahydrofolate, provides one carbon groups for the methylation of the amino acid homocysteine to methionine, a reaction in which vitamin B12 acts as a coenzyme. Methionine is the precursor to S-adenosylmethionine, the universal one carbon donor for methylation reactions, including DNA methylation. Since folate plays a substantial role in nucleotide synthesis, it was attributed in carcinogenesis action. Overwhelming consensus of epidemiologic evidence indicates that high folate status is associated with a reduced risk of CRC [4-9]. Paradoxically, a growing body of evidence suggests that high folate status is associated with an absolute risk of CRC [10-16]. The question, whether folate is CRC protector or promoter, has gained attention and has not been answered yet.

Obesity acts as an independent risk factor for malignant tumors of various organs including CRC [17]. The relative risk of CRC of obese patients is about 1.5 times higher than normal-weight individuals [18]. It is well known that leptin and insulin are associated with obesity. Several reports showed that leptin and insulin may act as CRC growth factors [19,20]. A meta-analysis showed that insulin therapy was positively associated with CRC risk [21]. However, recent studies showed the absence of associations between insulin, leptin and CRC risk [22]. Though leptin is secreted by adipocytes and cancerous tissue [20], the association between leptin levels and CRC risk has remained controversial.

The presence of controversial data relating several vitamins, hormones and CRC onset engaged us to investigate serum concentration of folate, vitamin B6, vitamin B12, homocysteine, insulin, and leptin in patients with CRC compared to healthy subjects. We also sought to establish the early involvement of folate in CRC onset.

Materials and Methods

Study population

Patient population consisted of 101 sporadic CRC cases who were admitted to department of medical oncology in Farhat Hached Hospital of Sousse (Tunisia). Patients’ diagnoses were based on cancer histology confirmation. For this study, the inclusion was restricted to newly diagnosed, non alcoholic patients and non multivitamins users. The TNM staging system was used to describe patients’ cancer stages.

Control population consisted of 130 healthy fasting volunteers belonging to the same socioeconomic group. Subjects with vitamin supplementation were excluded from the study. The study protocol was approved by the hospital ethical committee and informed consent was obtained from all subjects. An interviewer-administered questionnaire was completed about demographics, family history, and use of medication or supplements.

Laboratory measurements

Venous blood was collected prior to chemotherapy intervention.
Blood samples were collected from all subjects after an overnight fast into tubes with EDTA as anticoagulant. The tubes were immediately placed on crushed ice, protected from light and centrifuged within 20 minutes at 2000xg for 10 minutes. Plasma samples were then stored at -40° C until analysis.

**Folate:** 5-methyltetrahydrofolate acid was quantified using an automated analyzer system (AxSYM Abbott, Wiesbaden, Germany). The measure was based on an ion capture assay.

**Homocysteine:** Total homocysteine was estimated using an automated analyzer system (AxSYM Abbott, Wiesbaden, Germany). The measure was based on fluorescence polarization immunoassay technology.

**Vitamin B6:** Pyridoxal-5'-phosphate was quantified using an enzyme immunoassay (EIAb, Wuhan, China). The absorbance was measured at 450 nm using an ELISA microtiter plate reader (Tecan, Salzburg, Austria). Laboratory references were ranged between 0.5-30 nmol/l.

**Vitamin B12:** Cobalamin was quantified using an automated analyzer system (AxSYM Abbott, Wiesbaden, Germany). The measure was based on the microparticle enzyme immunoassay technology. Laboratory references were ranged between 40-900 pg/ml.

**Insulin:** Insulin was assessed using sandwich immunoradiometric assay (Immunotech, Beckman coulter company, Prague, Czech Republic). The bound radioactivity was determined by gamma counter (PC-RIA.MAS, Stratec). Laboratory references were ranged between 5-100 µIU/ml.

**Leptin:** Leptin was assessed using radioimmunometric assay (Linco Research, USA). The bound radioactivity was determined by gamma counter (PC-RIA.MAS, Stratec). Laboratory references were ranged between 1-80 ng/ml.

### Statistical analysis
Statistical analysis was performed by the SPSS 18. Patients and controls were divided into groups stratified according to gender and BMI value as follows: BMI  &lt; 23, 23-BMI &lt; 27 and BMI &gt; 27. Kolmogorov-Smirnov Z test was used to assess normality. For variables with normal distribution, Student t test was used. For variables without normal distribution, Mann Whitney test was used. Differences between patients and controls, cancer stages and folate, cancer stages and leptin and cancer stages and insulin were assessed by independent samples t-test. Correlation between folate acid and BMI was estimated using Pearson’s test. Data are expressed as mean value ± SD. P-value &lt; 0.05 was considered to be significant.

### Results
The average age was 48 years for controls and 56 years for patients (Table 1). Folic acid and vitamin B12 were significantly higher in patients compared to controls (Table 2). Folic acid and BMI were significantly inversely correlated in controls (r = -0.32; P ≤ 0.05). Homocysteine and vitamin B6 differences between patients and controls were not significant. Leptin and insulin were significantly higher in patients with BMI ≥ 27 kg/m² than in controls with BMI ≥ 27 kg/m² (Table 3). When cases were stratified into groups according to folate, leptin and insulin, we found no significant difference in cancer stages.

### Discussion
We reported here a significant increase of serum folate in colorectal incident cases compared to healthy controls (15 vs 10 ng/ml; P≤0.05). Epidemiological evidence revealed that high folate intake might enhance colorectal tumor recurrence and progression. One recent Meta-analysis data revealed that folic acid supplementary for 3 years had no effect on the adenoma recurrence while had an increased risk of adenoma lesion for those who received folic acid over 3 years [11]. An Aspirin/Folate Polyp Prevention Trial found an increased risk of advanced lesions with high malignant potential and an increased risk of having multiple adenomas among the folic acid supplementation group by providing folic acid for 6 years at 1 mg/day [16]. In contrast, in two large prospective cohorts, the Nurses’ Health Study and Health Professionals Follow-Up Study, higher pre-diagnostic levels of plasma folate were not associated with an increased risk of colorectal cancer specific or overall mortality [23]. It was reported that subjects with low plasma folate concentrations at baseline (≤ 7.5 ng/ml), supplemental folic acid decreased adenoma recurrence, whereas subjects with high folate concentrations at baseline (>7.5 ng/ml), supplemental folic acid had no significant effect [24]. A Japanese study found that patients with serum folate concentration greater than 8 ng/ml had the lowest risk of developing colorectal adenoma [25]. Multiple case-control and observational cohort studies suggest a reduction of 30%-40% in CRC risk for participants with high levels of folate intake compared to those with low levels [26]. According to some data [27], the risk of colorectal cancer decreases 11% for every 400 µg of total folate ingested. A trial showed that folic acid supplementation at 5 mg/day for 3 years in subjects with resected adenomas significantly reduced the number of recurrent adenomas [28]. Inconsistent results may due to polymorphism variations of folate metabolism enzymes. Genetic differences in folate metabolism due to polymorphism variations of folate metabolism enzymes. Genetic
The elevated plasma folate concentration in our non alcoholic patients, newly diagnosed and explored before carrying out their first chemotherapy provides evidence to folate supra-physiological concentrations in colon tumorigenesis. In fact, in order to assess the absolute involvement of folate in colon tumorigenesis we enrolled only newly diagnosed, non alcoholic patients. Blood samples were drawn before the first chemotherapy. Thus we eliminated factors (alcohol and chemotherapy molecules) interfering to folate metabolism. Alcohol is a folate antagonist that decreases its intestinal absorption and increases its excretion [32]. Moreover alcohol consumption was considered as CRC risk factor [33]. Blood samples were collected prior to chemotherapy in order to eliminate the interference of chemotherapy molecules such as leucovorin (LV, 5-formyltetrahydrofolate) which interferes with the chemotherapy in order to eliminate the interference of chemotherapy metastasis pathway have been investigated as potential colorectal cancer risk factor [33]. The high serum folate concentration in Tunisian people might influence the results.

In this study, we reported a significant negative correlation between BMI value and serum folate concentration in controls. According to Kant plasma volume and tissue folate distribution are possible factors underlying the inverse association folate-BMI [39]. However, the majority of incident cases were overweight, obese, and had high serum folate concentration.

In this study, insulin was significantly elevated in cases with BMI ≥ 27 kg/m² compared to controls with BMI ≥ 27 kg/m². The data supported the previous reports [40]. Leptin was also significantly increased in cases with BMI ≥ 27 kg/m² compared to controls with BMI ≥ 27 kg/m². We expected to find statistical connection between obesity indexes and cancer stages. However, neither insulin nor leptin were correlated to CRC stages.

Conclusions

The high plasma folate concentrations in our prediagnostic and non-alcoholic patients may provide additional evidence to the impact of folate supra-physiological concentrations in colon tumorigenesis. Molecular investigations, to explain the inverse association between BMI and plasma folate concentrations, are warranted.

Acknowledgment

We wish to thank all contributors from the Department of Medical Oncology, Farhat Hached University Hospital, Sousse, Tunisia.

References

5. Stevens VL, McCullough ML, Sun J, Jacobs EJ, Campbell PT, et al. (2011) High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology 141: 98-105, 105.


38. Tunisie: Nouvelles importations de blé.s
